


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jeffrey Schlom; Judith Kantor; Donald Kufe; Dennis Panicali; and Linda Gritz
Application No.: To be assigned (Con't of 09/366,670) Group No.: To be assigned
Filed: To be assigned (August 3, 1999) Examiner: To be assigned
For: RECOMBINANT POX VIRUS FOR IMMUNIZATION AGAINST MUC1
TUMOR-ASSOCIATED ANTIGEN

CERTIFICATE OF MAILING	
I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EL565093478US in an envelope addressed to Assistant Commissioner of Patents, Washington, D.C. 20231.	
Date: January 25, 2002	 Nicole M. Gignac

JCE79 U.S. PTO
10/057136
01/25/02

Assistant Commissioner for Patents
Washington D.C. 20231

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references cited in the attached Form PTO-1449.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	1	of	1	Application Number	To be assigned (con't of 09/366.670)
				Filing Date	To be assigned (08/03/1999)
				First Named Inventor	Jeffrey Schlom
				Art Unit	To be assigned
				Examiner Name	To be assigned
				Attorney Docket Number	700953-047113-C2

[illegible][illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	To be assigned (con't of 09/366,670)
		Filing Date	To be assigned (08/03/1999)
		First Named Inventor	Jeffrey Schlom
		Group Art Unit	To be assigned
		Examiner Name	To be assigned
		Attorney Docket Number	700953-047113-C2
Sheet	1	of	0

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Akagi, J. et al., J. Immunother. 20: 38-47 (1997).	
	CB	Balloul, J.-M. et al., Cell. Mol. Biol. 40 (Sup.1): 49-59 (1994).	
	CC	Bizouarne, N. et al., Breast Cancer Advances in Biology and Therapeutics; F. Calvo, M. Crepin, H. Magdelenat, eds.; John Liberty Eurotext, Vol. 21: 308-8 (1996).	
	CD	Graham, R.A. et al., Cancer Immunol. Immunther. 42: 71-80 (1996).	
	CE	Taylor-Papadimitriou, J and Epenetos, A., Tibtech 12: 227-33 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.